This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sequenom, Inc. (SQNM)
Q2 2012 Earnings Conference Call
July 26, 2012 5:00 PM ET
Marcy Graham - Senior Director, Investor Relations
Harry Hixson - Chairman and CEO
Paul Maier – CFO
Ron Lindsay - Director and EVP
Bill Welch - SVP, Diagnostics
Dirk van den Boom - SVP, Research &Development
Nandita Koshal - Barclays Capital
Bill Quirk - Piper Jaffray
Brian Weinstein - William Blair
Brandon Couillard – Jefferies & Co.
David Ferreiro – Oppenheimer & Co.
Zarak Khurshid - Wedbush Securities
Kevin DeGeeter - Ladenburg Thalmann & Co.
Junaid Husain – Dougherty & Company
Good afternoon, and welcome to the Sequenom’s Second Quarter 2012 Earnings Conference Call. All participants will be in listen-only-mode. (Operator Instructions). After today’s presentation, there will be an opportunity to ask questions. (Operator Instructions). Please note this event is being recorded.
And I would now like to turn the conference over to Marcy Graham, Senior Director, Investor Relations. Please go ahead.
Thank you, Emmy. Welcome to the Sequenom conference call to discuss operating results for the second quarter of 2012. Joining me today are Dr. Harry Hixson, Chairman and CEO, Paul Maier, CFO, Ron Lindsay, Director and Executive Vice President of Research and Development, Bill Welch, Senior Vice President of Diagnostics and Dr. Dirk van den Boom, Senior Vice President of Research and Development, both of whom will join us later for the Q&A portion of our call.
This call is also being broadcast live over the web and will be available for replay through August, 4
th on the investor section of our website at www.sequenom.com. Before we begin, please note that this call will include a discussion of Sequenom and Sequenom CMM’s current plans and intentions regarding operations and commercialization, including diagnostic test projections, goals, diagnostics test enhancements, operational enhancements and other matters, as well as expectations regarding Sequenom’s future financial performance and reporting.
Statements that are not historical facts, but are forward-looking statements. Forward-looking statements are not guarantees of performance, they involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.